Impact of rifampicin-inhibitable transport on the liver distribution and tissue kinetics of erlotinib assessed with PET imaging in rats

BACKGROUND: Erlotinib is an epidermal growth factor receptor (EGFR)-targeting tyrosine kinase inhibitor approved for treatment of non-small cell lung cancer. The wide inter-individual pharmacokinetic (PK) variability of erlotinib may impact treatment outcome and/or toxicity. Recent in vivo studies r...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:EJNMMI Res
Main Authors: Amor, Dorra, Goutal, Sébastien, Marie, Solène, Caillé, Fabien, Bauer, Martin, Langer, Oliver, Auvity, Sylvain, Tournier, Nicolas
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2018
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6095934/
https://ncbi.nlm.nih.gov/pubmed/30116910
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13550-018-0434-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados